anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Living donor liver transplantation using hepatic steatosis-improved grafts mitigates donor shortage. Herein, we aimed to evaluate the safety and feasibility of right-lobe adult-to-adult living donor liver transplantation using grafts improved through donor weight loss.
METHODS: In this retrospective study conducted in a single institution in the Republic of Korea, we reviewed the medical records of living liver donors who lost ≥ 10% of their body weight to improve steatosis before right lobe donation between January 2015 and December 2020. Overall, 1040 right-lobe donors were included, with 150 and 890 donors in the weight loss and control (non-steatosis) groups, respectively.
RESULTS: We performed 1:1 individual matching using the greedy matching method, by which 124 patients were included in each group. The median period from the date of the first visit to donation was 113 (interquartile range: 78-184) days in the weight loss group. As body weight changed from 82.8 ± 13.7 kg to 70.8 ± 11.8 kg (p < 0.0001), body mass index also improved from 27.8 ± 3.9 kg/m2 to 23.8 ± 3.1 kg/m2 (p < 0.0001). No significant between-group differences existed in the postoperative laboratory data for living donors and recipients. The incidence of postoperative complications in donors was comparable between the groups (control group, 9.7%; weight loss group, 13.7%; p = 0.3185). The graft and recipient survival rates were comparable between the groups (p = 1.000).
CONCLUSION: Weight loss through diet and exercise significantly could improve hepatic steatosis in living donor candidates for liver transplantation, with the surgical outcomes in recipients and donors being equivalent to those in recipients and non-steatotic donors.
This is a non-randomized clinical trial pilot study. Consenting adult (≥ 18 years) women with stage II-III breast cancer undergoing will receive neoadjuvant chemotherapy with a standard ACT regimen prior to mastectomy. Prior to beginning chemotherapy, patients will receive a baseline mammogram, breast HD PET/CT, and blood draw. Not more than 7 days prior to the second cycle of chemotherapy, patients will have both HD PET/CT and diagnostic mammography images taken to assess early response to treatment. Patients will have two additional mammography and HD PET/CT examinations: one after the first cycle of chemotherapy, and another upon completion of the last cycle of chemotherapy but before mastectomy. The investigators will collect data on the size (maximum diameter, estimated volume) and 18FDG uptake (SUV) of the known primary breast cancer on HD PET/CT. Blood will be sampled from patients at 12 separate time points during the study for glycan analysis. At least 3 ml will be taken with each blood draw. The first blood draw will be taken when the patient agrees to enroll in the study. The second blood draw will be taken prior to the first cycle of chemotherapy. Thereafter, blood will be drawn for serum glycan analysis after each cycle of chemotherapy is completed. After the patient undergoes mastectomy, tissue will be collected for MUC-1 assay and two additional blood draws will be taken.
Procedure for obtaining an antilipemic agent containing a fraction of soybean oil. Consists of the following stages: 1. Distillation in steam current of a gross soybean oil obtaining a deodorized extract of soybean oil. 2. Reaction of methanol with the extract to convert the fatty acids in the corresponding methyl esters. 3. Molecular distillation at 170-190ºc and 20-130 hg. To produce an insaponifiable fraction, vegetable esterols constitute approximately 45 per 100 in weight, and tocopherols, around 20 per 100 in weight of such fraction; fatty acids are approximately 28-42 per 100 in weight. (Machine-translation by Google Translate, not legally binding)
The invention discloses the preparation of a multifunctional Cu3BiS3-PEG-FITC&Gd-DTPA nano composite material and an application of the composite material in multi-mode imaging and photo-thermal treating and belongs to the field of inorganic nano materials. The nano composite material is in the form of nano particles which are prepared through a high-temperature pyrolysis method with oleic acid, oleylamine and octadecylene as reaction solvents, Cu(NO3)2.3H2O and Bi(NO3)3.5H2O as raw materials and sodium diethyldithioaminoformate as a complexing agent and a sulfur sources. The Cu3BiS3 nano particle has excellent absorption in a near-infrared light zone. A test result proves that the Cu3BiS3 nano particle is excellent in photo-thermal effect. By means of H2N-PEG-NH2 for improving water solubility, the nano particles are transferred from the oily solvent to water, wherein amino groups are formed on the surface of the nano particles, so that a fluorescent substance FITC and Gd-DTPA used for magnetic resonance imaging (MRI) are connected to the nano particles covalently. The Cu3BiS3 ternary chalcogenide nano particles can be used for CT imaging, so that the Cu3BiS3 nano particles can be used for multi-mode imaging (including fluorescent imaging, MRI and CT imaging) and photo-thermal treatment and have a good prospect in the field of biological application.
Patient is scheduled for or has undergone primary total knee arthroplasty (TKA) using a Persona Personalized Knee System with Canary Tibial Extension (PIQ) TKA implant according to the appropriate surgical technique and IFU. If you decide to take part in this research study, the general procedures include one follow-up visit where you will be asked to complete two performance-based tests that are used to assess your physical function following Total Knee Arthroplasty ("TKA"). As part of your standard of care, you will receive a Zimmer Persona® Personalized Knee System with Canary canturioTM (CTE) tibial extension. As part of this study, subjects will be asked to perform two performance based tests called the 4 meter walk test and the timed up and go test. Subjects will also be asked to complete a series of patient questionnaires that will assess their post-operative function.
Ketamine and Esketamine intravenous perfusions in Pain Clinic can modulate chronic pain and are therefore part of the therapeutic arsenal of the Anesthesiologist in pain management. Patients with fibromyalgia syndrome have elevated levels of glutamate in the brain. This is demonstrated by functional brain imaging techniques. Elevation of glutamate is demonstrated in the posterior insular cortex, positively correlating with lower pain thresholds which is a hallmark of fibromyalgia syndrome. Ketamine has (e.a.) an inhibitory role of the N-methyl-D-aspartate (NMDA) receptor: it is a non-competitive antagonist of the NMDA receptor. In this context, Esketamine is available recently. This is the levorotatory form of Ketamine.

The main objective of this study is to measure if there is a difference between Ketamine and Esketamine on patients with fibromyalgia syndrome via the fibromyalgia impact questionnaire (FIQ) and measurement of side effects after intravenous perfusion. The fibromyalgia impact questionnaire is a global assessment of symptoms: pain, function, fatigue, stiffness, discomfort when walking up stairs, difficulties at work, anxiety, depression, days not worked and days of good quality in the past week.
Fibromyalgia Syndrome (FMS), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID (LC) are similar multisymptom clinical syndromes but with difference in dominant symptoms in each individual. There is existing and emerging literature on possible functional alterations of the central nervous system in these conditions. This review aims to synthesise and appraise the literature on resting-state quantitative EEG (qEEG) in FMS, ME/CFS and LC, drawing on previous research on FMS and ME/CFS to help understand neuropathophysiology of the new condition LC. A systematic search of MEDLINE, Embase, CINHAL, PsycINFO and Web of Science databases for articles published between December 1994 and September 2023 was performed. Out of the initial 2510 studies identified, 17 articles were retrieved that met all the predetermined selection criteria, particularly of assessing qEEG changes in one of the three conditions compared to healthy controls. All studies scored moderate to high quality on the Newcastle-Ottawa scale. There was a general trend for decreased low-frequency EEG band activity (delta, theta, and alpha) and increased high-frequency EEG beta activity in FMS, differing to that found in ME/CFS. The limited LC studies included in this review focused mainly on cognitive impairments and showed mixed findings not consistent with patterns observed in FMS and ME/CFS. Our findings suggest different patterns of qEEG brainwave activity in FMS and ME/CFS. Further research is required to explore whether there are phenotypes within LC that have EEG signatures similar to FMS or ME/CFS. This could inform identification of reliable diagnostic markers and possible targets for neuromodulation therapies tailored to each clinical syndrome.
The present invention addresses the problem of providing: a 3-substituted uracil compound that has excellent germicidal/antimicrobial activity and excellent safety, while being industrially beneficially synthesized; and an agricultural/horticultural germicide containing the compound as an active ingredient. Further, the present invention addresses the problem of providing a nematicide containing the aforesaid compound as an active ingredient. Furthermore, the present invention addresses the problem of providing a medical and animal antifungal agent containing the aforesaid compound as an active ingredient.　Provided is a compound represented by formula (I) or a salt thereof.　In formula (1): Y represents an oxygen atom, etc.; X1 and X2 each independently represent a hydrogen atom, a halogeno group, a substituted or unsubstituted C1-6 alkyl group, etc.; X3 represents a group represented by RN1-CO-NRN2-, etc.; RN1 and RN2 each independently represent a hydrogen atom, a substituted or unsubstituted linear C1-6 alkyl group, etc.; A represents a substituted or unsubstituted C1-6 alkylene group, etc.; and Q represents a substituted or unsubstituted C6-10 aryl group, etc.
One dosage of Chinese herbal medicine by oral administration per day for 8 weeks. For patients who cannot take oral medicine can be switched to colon route by the colonic therapy system（IMS-100A produced by Sunny Medical in Beijing China).
1,142,578. Delta modulation systems. NIPPON ELECTRIC CO. Ltd. 9 Feb., 1967 [8 March, 1966], No. 6331/67. Heading G4H. A speech signal at input 11 is applied to a subtracter 12 controlling a delta modulation encoder 13, the other input of subtractor 12 being a feed-back signal derived from the delta modulation output by way of a decoder 16 having a hyperbolic characteristic. The overall characteristic of the transmitter is thus also hyperbolic and gives an improved signal-tonoise ratio. The decoder 16 comprises an integrator 162, a filter 163 which derives a D.C. level signal from the output of integrator 162, a circuit 165 which adds a D.C. bias level at 164 to the output of filter 163, and a circuit 161 which determines the quantizing steps applied to integrator 162. The output of summing circuit 165 may be switched by circuit 161 to integrator 162 with a polarity determined by the delta modulation pulse applied to the other input of 161, or circuit 161 may durationmodulate the delta modulation pulses in accordance with the output of circuit 165.
Male and female patients at least 18 years old with untreated Non-small Cell Lung Cancer who have non-incisional biopsy definitive evidence of disease (or cytology results from a bronchoscope procedure confirming NSCLC) and who have been previously certified (per Centers for Medicare and Medicaid Services requirements)by their physicians will be consented for the study. The study consists of a screening visit, gold-standard 18F-FDG PET/CT imaging followed by the investigational agent 99mTc-EC-DG with SPECT/CT(if the PET/CT was performed as part of the pre-study activities on a qualified PET camera for this study, the SPECT/CT must be done within 45 days of the PET/CT imaging procedures). The study procedures can be performed within 5-7 days of signing the informed consent. During the 99mTc-EC-DG SPECT/CT visit of the study, pharmacokinetic (PK) blood draws and urine collection will be taken and radiation dosimetry (Planar Imaging) will be performed at specified time points post 99mTc-EC-DG injection. Patients will be seen 24 hours after the 99mTc-EC-DG injection for safety and final PK blood and urine collection. A 21-day follow-up period (after the SPECT/CT image) will allow the investigator to acquire additional imaging, surgical, pathology and treatment documentation (an actual patient visit is not required at the 21 day follow-up time point).
The disclosure concerns a process for the manufacture of basic aluminium chlorides in powder form for antiperspirant use which have an aluminium:chloride molar ratio of 1.7:1 to 2.2:1 and has a Band III fraction of at least 20% as determined by a chromatographic procedure. The disclosure centers on the finding of advantageous reaction conditions for the known reaction between aluminium powder and an aqueous aluminium chloride solution. The temperature of reaction is 50° to 105° C. and the final aluminium concentration of the solution is 7.5% to 13%. It has been discovered that if this reaction is carried out sufficiently rapidly a solution of a basic aluminium chloride is produced having a Band III fraction of at least 20%. The disclosure shows the influence of the grade of aluminium and manner of conducting the reaction on reaction time. The solution obtained is dried, preferably spray dried or freeze dried, to give the powder.
The CHP intervention is a three session intervention that occurs once a week for three weeks. The CHP intervention will be delivered by MI-trained mental health counselors. The CHP intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
This study pilot tests a 13-week distress tolerance-based psychosocial intervention paired with a benzodiazepine taper comparing it to a relaxation therapy control condition with the aim of assisting individuals receiving OAT discontinue benzodiazepine use. All participants will receive the same benzodiazepine (BZD) discontinuation protocol. The Distress Tolerance-Benzodiazepine Discontinuation (DT-BD) intervention consists of 13 weeks with 5 weekly therapy sessions prior to a 9-week BZD taper. Some participants may be prescribed non-benzodiazepine medications to treat the underlying conditions for which they were using BZDs \[e.g. selective serotonin reuptake inhibitors (SSRI) for anxiety or hypnotics for insomnia\]. Data collection will occur at baseline, then weekly for 13 weeks.
Autism spectrum disorder (ASD) is a complex neurodevelopmental condition with considerable genetic heterogeneity. The disorder is clinically diagnosed based on DSM-5 criteria, featuring deficits in social communication and interaction, along with restricted and repetitive behaviours. Here, we performed whole-genome sequencing (WGS) on four individuals with ASD from two multiplex families (MPX), where more than one individual is affected, to identify potential single nucleotide variants (SNVs) and structural variants (SVs) in coding and non-coding regions. A rigorous bioinformatics pipeline was employed for variant detection, followed by segregation analysis. Our investigation revealed an unreported splicing variant in the DYRK1A gene (c.-77 + 2T > C; IVS1 + 2T > C; NM_001396.5), in heterozygote form in two affected children in one of the families (family B), which was absent in the healthy parents and siblings. This finding suggests the presence of gonadal mosaicism in one of the parents, representing the first documented instance of such inheritance for a variant in the DYRK1A gene associated with ASD. Furthermore, we identified a 50 bp deletion in intron 9 of the DLG2 gene in two affected patients from the same family, confirmed by PCR and Sanger sequencing. In Family A, we identified potential candidate variants associated with ASD shared by the two patients. These findings enhance our understanding of the genetic landscape of ASD, particularly in MPX families, and highlight the utility of WGS in uncovering novel genetic contributions to neurodevelopmental disorders.
After fulfilling the inclusion criteria and being randomly assigned to this group, the patients undergo scaling and root planning by the consultant. Baseline values are recorded, 1ml of the combination of 1% metronidazole gel and 2% minocycline gel is applied subgingivally. The patients are instructed not to spit or rinse for at least one hour. Then patients are advised oral hygiene instructions i.e., proper brushing and flossing. They are recalled after 7 and 15 days and all clinical parameters are rerecorded.
Obesity is a public health problem. Currently, the best treatment is surgery. However, 15% of patients after surgery have problems such as nausea, pain, vomiting, heartburn or regurgitation. To investigate these problems, an endoscopy is used. Yet, endoscopy has some disadvantages such as the need for intravenous sedation, need to take time off work, need for special endoscopy units and nurses and a delay in diagnosing because the endoscopy cannot be done at the time of the clinic visit. A new technology called clinic-based nasopharyngoendoscopy can potentially solve many of the problems with the current endoscopy. This study aims to determine that this new technology is just as effective in diagnosing problems as the current gold standard.
This application discloses a kind of specificity antibody screening methods for not synantigen.Include the following steps：A. anti-normal cell or the serum of normal structure are obtained；B. antiserum purified polyclonal antibodies step A obtained, and the polyclonal antibody is coupled on gel micro-ball；C. it cracks corresponding cancer cell or cancerous issue obtains its lysate；D. using the affinity column for being coupled anti-normal cell or normal structure polyclonal antibody remove in corresponding cancer cell or cancerous issue with normal identical part；E. the uncombined part of affinity column detaches B cell as antigen-immunized animal after immune；F. B cell and SP2/0 cell fusions after detaching, obtain cell strain of monoclonal antibody；Monoclonal antibody is prepared with cell strain of monoclonal antibody.11 kinds of antibody that the present invention filters out directly are screened with HepG2 cells, that is to say, that not by the negative screening of HH cell or other cells.
This cluster of four homes will receive robot animals four months after commencement of the 8 month trial. The four months without robots will serve as a control period.
The present invention relates to the application of geldanamycin in the preparation of a medicine for treating condyloma acuminata. The geldanamycin has no stimulation effect on the inner side skin of the thigh of a healthy calf and has the effect on inhibiting the duplication of bovine papilloma virus DNA so that a papilloma body is atrophied, aged and lessened. The present invention also relates to the application of the geldanamycin in the preparation of a medicine for treating herpes virus genital tract affection. C-3559 has a broad-spectrum antivirus effect during the culture of cells and micromole level antivirus activity on various DNA and RNA viruses. Through 41 generation transfer in vitro, the medicine-resistant toxic strains of HSV-1 viruses on the geldanamycin are not separated. A 15th HSV-1 GA medicine-resistant training generation has the same acyclovir sensitivity with wild strains, and geldanamycin without cell toxicity concentration can specially inhibit the synthesis of HSV-1 DNA. In a herpes virus 2 type genital tract affection model of a small white mouse; the duplication of the 2 type herpes viruses can be effectively inhibited, and the virus excretion quantity can be obviously reduced. The death rate of a small white mouse is decreased, the average living day of a small affected white mouse is prolonged, and the effect is superior to that of acyclovir with the same dosage. All dosage groups have no influence on the weight increase of the small white mouse.
Decreased nicotinamide adenine dinucleotide (NAD+) levels contribute to various pathologies such as ageing, diabetes, heart failure and ischemia-reperfusion injury (IRI). Nicotinamide riboside (NR) has emerged as a promising therapeutic NAD+ precursor due to efficient NAD+ elevation and was recently shown to be the only agent able to reduce cardiac IRI in models employing clinically relevant anesthesia. However, through which metabolic pathway(s) NR mediates IRI protection remains unknown. Furthermore, the influence of insulin, a known modulator of cardioprotective efficacy, on the protective effects of NR has not been investigated. Here, we used the isolated mouse heart allowing cardiac metabolic control to investigate: (1) whether NR can protect the isolated heart against IRI, (2) the metabolic pathways underlying NR-mediated protection, and (3) whether insulin abrogates NR protection. NR protection against cardiac IRI and effects on metabolic pathways employing metabolomics for determination of changes in metabolic intermediates, and 13C-glucose fluxomics for determination of metabolic pathway activities (glycolysis, pentose phosphate pathway (PPP) and mitochondrial/tricarboxylic acid cycle (TCA cycle) activities), were examined in isolated C57BL/6N mouse hearts perfused with either (a) glucose + fatty acids (FA) ("mild glycolysis group"), (b) lactate + pyruvate + FA ("no glycolysis group"), or (c) glucose + FA + insulin ("high glycolysis group"). NR increased cardiac NAD+ in all three metabolic groups. In glucose + FA perfused hearts, NR reduced IR injury, increased glycolytic intermediate phosphoenolpyruvate (PEP), TCA intermediate succinate and PPP intermediates ribose-5P (R5P) / sedoheptulose-7P (S7P), and was associated with activated glycolysis, without changes in TCA cycle or PPP activities. In the "no glycolysis" hearts, NR protection was lost, whereas NR still increased S7P. In the insulin hearts, glycolysis was largely accelerated, and NR protection abrogated. NR still increased PPP intermediates, with now high 13C-labeling of S7P, but NR was unable to increase metabolic pathway activities, including glycolysis. Protection by NR against IRI is only present in hearts with low glycolysis, and is associated with activation of glycolysis. When activation of glycolysis was prevented, through either examining "no glycolysis" hearts or "high glycolysis" hearts, NR protection was abolished. The data suggest that NR's acute cardioprotective effects are mediated through glycolysis activation and are lost in the presence of insulin because of already elevated glycolysis.